0000000000607183
AUTHOR
David Gordon
showing 2 related works from this author
Efficacy and Safety of Subcutaneous Belimumab in Anti–Double-Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus
2018
Objective: To investigate the efficacy and safety of belimumab, a human immunoglobulin monoclonal antibody against B lymphocyte stimulator, in a subset of patients with systemic lupus erythematosus (SLE) who were hypocomplementemic (C3 <90 mg/dl and/or C4 <10 mg/dl) and anti–double-stranded DNA (anti-dsDNA) positive (≥30 IU/ml) at baseline. Methods: In this phase III, double-blind, placebo-controlled study (BEL112341; ClinicalTrials.gov identifier: NCT01484496), patients with moderate to severe SLE (Safety of Estrogens in Lupus Erythematosus National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index [SELENA–SLEDAI] score ≥8) were randomized (2:1) to receive weekl…
Who Punishes? : The Status of the Punishers Affects the Perceived Success of, and Indirect Benefits From, “Moralistic” Punishment
2016
‘‘Moralistic’’ punishment of free riders can provide a beneficial reputation, but the immediate behavior is costly to the punisher. In Study 1, we investigated whether variation in status would be perceived to offset or mitigate the costs of punishment. One hundred and nineteen participants were presented with a vignette describing a punishment scenario. Participants predicted whether punishment would occur, how successful it would be, and indicated their attitude to the punisher. Participants believed only intervention by a high-status (HS) individual would be successful and that low-status (LS) individuals would not intervene at all. HS individuals predicted to punish successfully were se…